Stem cell trick may let kidney patients ditch daily pills

NCT ID NCT00619528

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving donor stem cells and a drug called Campath-1H can help kidney transplant recipients stop taking anti-rejection medications permanently. Eighty-eight patients receiving a kidney from an identical sibling will get the stem cell infusions and temporary immunosuppression. The goal is to see if the body accepts the new kidney without needing lifelong drugs, with follow-up lasting up to 10 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
donor hematopoietic stem cells and Campath-1H
What this could lead to
If successful, this could allow kidney transplant recipients to stop taking lifelong immunosuppressive drugs without rejecting the new kidney.
What could go wrong
This is an early-stage study with only 88 participants, and not all patients may achieve drug-free tolerance. There are risks of infection, graft rejection, or side effects from the conditioning regimen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Northwestern Memorial Hospital

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.